A drug rollout that officials hailed as a demonstration that the UK was still a “science superpower,” has reached only a fraction of eligible patients.NHS England announced in 2021 that 300 000 people would get the “revolutionary new” anti-cholesterol drug inclisiran (Leqvio) by autumn 2024 and that that figure could rise to “nearly half a million people beyond the initial period.”But The BMJ has found that just 30 000 patients have been prescribed the drug in primary care since 2021, meaning that just one in 10 of the patients that officials aimed to reach by 2024 have actually received it.Inclisiran is a twice yearly injection that can be used in patients who have a history of cardiovascular events and persistently high levels of low density lipoproteins despite taking the maximum tolera

See Full Page